{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:49Z","timestamp":1787004829229,"version":"build-2736575974"},"reference-count":127,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1053\/j.seminoncol.2015.09.032","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T15:23:37Z","timestamp":1443108217000},"page":"863-875","source":"Crossref","is-referenced-by-count":35,"title":["Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management"],"prefix":"10.1053","volume":"42","author":[{"given":"Sariah","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2015.09.032_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrd1720","article-title":"Elucidating mechanisms of drug-induced toxicity","volume":"4","author":"Liebler","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ceb.2009.01.028","article-title":"Tyrosine phosphorylation: thirty years and counting","volume":"21","author":"Hunter","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbior.2012.10.006","article-title":"Receptor tyrosine kinase signaling mechanisms: devolving TrkA responses with phosphoproteomics","volume":"53","author":"Bradshaw","year":"2013","journal-title":"Adv Biol Regul"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab\u2014an antibody against epidermal growth factor receptor: systemic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib7","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886)","volume":"29","author":"Balagula","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2133.2009.09536.x","article-title":"Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines","volume":"162","author":"Han","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib10","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1158\/1078-0432.CCR-11-0545","article-title":"The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab","volume":"17","author":"Perez-Soler","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib12","doi-asserted-by":"crossref","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","article-title":"Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clpt.2006.04.007","article-title":"Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer","volume":"80","author":"Lu","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib14","article-title":"Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity","author":"Jaka","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3892\/or_00000319","article-title":"Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis","volume":"21","author":"Orditura","year":"2009","journal-title":"Oncol Rep"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-013-0257-x","article-title":"The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials","author":"Petrelli","year":"2013","journal-title":"Target Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ctrv.2014.05.003","article-title":"Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms","volume":"40","author":"Liu","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","article-title":"Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-015-0132-9","article-title":"CA-SSR1 polymorphism in intron 1 of the EGFR gene in patients with malignant tumors who develop acneiform rash associated with the use of cetuximab","author":"Jarzabek","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.tpj.6500444","article-title":"Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib","volume":"8","author":"Liu","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2009-0055","article-title":"Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K","volume":"14","author":"Thatcher","year":"2009","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"Azad","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archderm.144.6.779","article-title":"Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib","volume":"144","author":"Hong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib27","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib28","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib29","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib30","first-page":"30","article-title":"Updated safety and efficacy results from a phase I\/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1\/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamadermatol.2013.2023","article-title":"Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib","volume":"149","author":"Falchook","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib33","unstructured":"GlaxoSmithKline. Pazopanib prescribing information. https:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/VOTRIENT-PI-MG.PDF, 2013."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib34","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib35","unstructured":"FDA. COMETRIQ prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203756lbl.pdf, 2012."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-008-0409-1","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2340\/00015555-1289","article-title":"Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib","volume":"92","author":"Brazzelli","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1472-6823-13-29","article-title":"Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib","volume":"13","author":"Hussain","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib40","doi-asserted-by":"crossref","first-page":"176S","DOI":"10.1038\/jid.1993.73","article-title":"White mutants in mice shedding light on humans","volume":"100","author":"Halaban","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1006\/cyto.1999.0614","article-title":"Autocrine and paracrine regulation by cytokines and growth factors in melanoma","volume":"12","author":"Lazar-Molnar","year":"2000","journal-title":"Cytokine"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib42","first-page":"1058","article-title":"Mutations of the KIT (mast\/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism","volume":"51","author":"Spritz","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0014-4827(92)90189-F","article-title":"The ret oncogene can induce melanogenesis and melanocyte development in Wv\/Wv mice","volume":"200","author":"Iwamoto","year":"1992","journal-title":"Exp Cell Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/jpet.103.052530","article-title":"Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans","volume":"307","author":"Moss","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib45","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/jnci\/djj469","article-title":"Pharmacogenetics of ABCG2 and adverse reactions to gefitinib","volume":"98","author":"Cusatis","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib46","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/j.1464-410X.2010.09985.x","article-title":"Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use","volume":"107","author":"Kirkali","year":"2011","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib47","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-2403","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors","author":"Papadopoulos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib48","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","article-title":"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors","volume":"18","author":"Hong","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib49","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib50","unstructured":"Genentech. Avastin prescription information. http:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf, 2013."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/pgs.10.172","article-title":"Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients","volume":"12","author":"Lemos","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000086971","article-title":"Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer","volume":"68","author":"Karthaus","year":"2005","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib54","article-title":"Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis","author":"Qi","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib55","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cursur.2006.06.002","article-title":"Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management","volume":"63","author":"Heinzerling","year":"2006","journal-title":"Curr Surg"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib59","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","article-title":"Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients","volume":"116","author":"Sonis","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1529-8019.2010.01324.x","article-title":"Aphthous ulcers","volume":"23","author":"Messadi","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib62","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/cncr.28634","article-title":"A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy","volume":"120","author":"Garcia","year":"2014","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib63","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib64","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib65","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib66","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1108-1187","article-title":"Angiogenesis factors and preeclampsia","volume":"14","author":"Dechend","year":"2008","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib67","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib68","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/annonc\/mds179","article-title":"Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib","volume":"23","author":"George","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/bjc.2011.2","article-title":"Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy","volume":"104","author":"Osterlund","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib70","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12032-012-0327-4","article-title":"Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients","volume":"30","author":"Tahover","year":"2013","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib72","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib73","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00280-012-2028-2","article-title":"Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer","volume":"71","author":"Morita","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib74","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/cncr.26491","article-title":"Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2015.02.007","article-title":"Genotype correlations with blood pressure and efficacy from a randomized phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma","author":"Escudier","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.dld.2014.12.013","article-title":"Vascular endothelial growth factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer","volume":"47","author":"Sibertin-Blanc","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib77","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib78","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2005.04.5740","article-title":"Angiogenesis inhibitors and hypertension: an emerging issue","volume":"24","author":"Sica","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib80","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib81","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib82","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1200\/JCO.2003.99.046","article-title":"bleeding, thrombosis, and warfarin","volume":"21","author":"Kilickap","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib83","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdr463","article-title":"Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts","volume":"23","author":"Reck","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib84","unstructured":"FDA. FDA approval of Ramucirumab, 2014, pp http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm426735.htm."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib85","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1378\/chest.127.6.2113","article-title":"Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis","volume":"127","author":"Valipour","year":"2005","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib86","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib87","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib88","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib89","unstructured":"Iclusig.com. Posatinib toxicity. http:\/\/www.iclusig.com\/ 2013."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib90","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.21277","article-title":"Hemostatic complications of angiogenesis inhibitors in cancer patients","volume":"83","author":"Elice","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib91","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib92","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00280-013-2146-5","article-title":"Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors","volume":"71","author":"Deeken","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib93","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/annonc\/mds130","article-title":"Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs","volume":"23","author":"Naing","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib94","unstructured":"AstraZeneca. Vandetanib package insert. http:\/\/www1.astrazeneca-us.com\/pi\/vandetanib.pdf 2011."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib95","unstructured":"European-Medicines-Agency. Nilotinib product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000798\/WC500034394.pdf, 2013."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib96","unstructured":"Norvartis. Nilotinib package insert. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf, 2010."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib97","unstructured":"Pfizer. Crizotinib package insert. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202570s002lbl.pdf, 2011."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib98","unstructured":"GlaxoSmithKline. Lapatinib package insert. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s007lbl.pdf, 2013."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib99","doi-asserted-by":"crossref","first-page":"131ra50","DOI":"10.1126\/scitranslmed.3003623","article-title":"Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome","volume":"4","author":"Lu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib100","unstructured":"AstraZeneca. Iressa prescribing information. http:\/\/www.iressa.com\/_mshost5259502\/content\/6906430\/Gefitinib-product-informationasdad, 2010."},{"key":"10.1053\/j.seminoncol.2015.09.032_bib101","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1548-5315(11)70508-3","article-title":"Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases","volume":"5","author":"Brown-Glberman","year":"2008","journal-title":"Commun Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib102","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","article-title":"HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer","volume":"29","author":"Spraggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib103","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/hep.20215","article-title":"HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease","volume":"39","author":"Andrade","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib104","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1200\/JCO.2010.34.3368","article-title":"Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism","volume":"29","author":"Kijima","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib105","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib106","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Renouf","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib107","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"van der Noll","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib108","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncr.10729","article-title":"Severe periorbital edema secondary to STI571 (Gleevec)","volume":"95","author":"Esmaeli","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib109","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib110","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib111","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","article-title":"Mechanism and management of AKT inhibitor-induced hyperglycemia","volume":"15","author":"Crouthamel","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib112","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib113","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1158\/1078-0432.CCR-12-0061","article-title":"Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing\u2019s sarcoma family tumors","volume":"18","author":"Naing","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib114","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clgc.2012.08.002","article-title":"Thyroid dysfunction in patients treated with sunitinib or sorafenib","volume":"10","author":"Clemons","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib116","article-title":"Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors","author":"Bailey","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib117","doi-asserted-by":"crossref","first-page":"463","DOI":"10.18632\/oncotarget.886","article-title":"A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal","volume":"4","author":"Janku","year":"2013","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib118","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccr.2008.03.015","article-title":"Survival of cancer cells is maintained by EGFR independent of its kinase activity","volume":"13","author":"Weihua","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib119","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib121","first-page":"487","article-title":"More on aprepitant for erlotinib-induced pruritus","volume":"364","author":"Mir","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib122","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","article-title":"Drug interactions with solid tumour-targeted therapies","volume":"89","author":"Thomas-Schoemann","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib123","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CAD.0b013e32835aa5fd","article-title":"Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature","volume":"24","author":"Lombardi","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib124","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"Perez-Soler","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors","volume":"34","author":"Teng","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib126","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF03261934","article-title":"Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study","volume":"51","author":"Joerger","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.seminoncol.2015.09.032_bib127","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541500202X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541500202X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T06:22:27Z","timestamp":1718086947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377541500202X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S009377541500202X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.032","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}